Encainide
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Enkaid |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605040 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H28N2O2 |
Molar mass | 352.478 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Encainide (trade name Enkaid) is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects.[1]
Synthesis
[edit]![](http://178.128.105.246/content-http-upload.wikimedia.org/wikipedia/commons/thumb/f/f7/Encainide_synthesis.svg/500px-Encainide_synthesis.svg.png)
See also
[edit]References
[edit]- ^ Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". The New England Journal of Medicine. 324 (12): 781��8. doi:10.1056/NEJM199103213241201. PMID 1900101.
- ^ Dykstra SJ, Minielli JL, Lawson JE, Ferguson HC, Dungan KW (September 1973). "Lysergic acid and quinidine analogs. 2-(o-Acylaminophenethyl)piperidines". Journal of Medicinal Chemistry. 16 (9): 1015–20. doi:10.1021/jm00267a012. PMID 4745503.